HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

compound 348U87

structure given in first source; antiherpes cpd

Also Known As:

2-actylpyridine 5-((2-chloroanilino)thiocarbonyl)thiocarbonohydrazone; 348 U87; 348U87; BW 348U87; BW-348U87

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrazines: 379
  - Hydrazones: 500
    - compound 348U87: 4
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - compound 348U87: 4

Related Diseases

1.	Herpes Simplex 05/01/1993 - "We treated 10 human immunodeficiency virus-infected patients with acyclovir-resistant anogenital herpes simplex virus infection with a topical preparation of 348U87 (3%) in combination with acyclovir (5%) in an open-labelled study. " 04/01/1994 - "Solar simulator-induced herpes simplex labialis: use in evaluating treatment with acyclovir plus 348U87." 01/01/1993 - "Potential for combined therapy with 348U87, a ribonucleotide reductase inhibitor, and acyclovir as treatment for acyclovir-resistant herpes simplex virus infection."
2.	Infections 05/01/1992 - "BW 348U87 and ACV are currently being developed as a combination topical therapy for cutaneous herpes infections." 01/01/1993 - "We performed a pilot study of topical combination therapy with 348U87 (3%) and acyclovir (5%) cream for acyclovir-resistant, anogenital HSV infections in ten human immunodeficiency virus (HIV)-infected patients. " 05/01/1993 - "Topical treatment of infection with acyclovir-resistant mucocutaneous herpes simplex virus with the ribonucleotide reductase inhibitor 348U87 in combination with acyclovir." 01/01/1993 - "In addition, the combination of the ribonucleotide reductase inhibitor 348U87 and acyclovir has synergistic therapeutic effects against infections in mice due to thymidine kinase-deficient, thymidine kinase-altered, and DNA polymerase mutants of HSV. "
3.	Herpes Labialis (Fever Blister) 04/01/1994 - "We next evaluated the effects of combined therapy with topical ACV and 348U87, a ribonucleotide reductase inhibitor, begun immediately after UV exposure for the prevention and treatment of herpes labialis. "

Related Drugs and Biologics

1.	Acyclovir (Aciclovir)
2.	Ribonucleotide Reductases (Ribonucleotide Reductase)
3.	Therapeutic Uses
4.	Thymidine Kinase
5.	DNA-Directed DNA Polymerase (Polymerases, DNA)

Related Therapies and Procedures

1.	Therapeutics